PapersFlow Research Brief
Cancer survivorship and care
Research Guide
What is Cancer survivorship and care?
Cancer survivorship and care is the cluster of research addressing quality of life, psychosocial aspects, patient-reported outcomes, depression, anxiety, physical activity, symptom management, and well-being in individuals who have undergone cancer treatment.
This field encompasses 73,105 works focused on instruments like the EORTC QLQ-C30 and FACT scale for measuring health-related quality of life in cancer patients. Key studies validate tools such as the Multidimensional Fatigue Inventory for assessing fatigue and the PHQ-15 for somatic symptom severity. Survivorship statistics from 2012, 2019, and 2022 document the increasing number of cancer survivors due to population aging, growth, and treatment advances.
Topic Hierarchy
Research Sub-Topics
Cancer-Related Fatigue Management
This sub-topic investigates the pathophysiology, assessment, and interventions for cancer-related fatigue in survivors. Researchers evaluate exercise and pharmacological approaches.
Psychosocial Interventions for Cancer Survivors
This sub-topic covers cognitive-behavioral therapy, mindfulness, and support groups for anxiety and depression in cancer survivorship. Researchers measure long-term psychological outcomes.
Patient-Reported Outcomes in Oncology
This sub-topic focuses on validation and application of tools like EORTC QLQ-C30 and FACT for assessing health-related quality of life. Researchers integrate PROs into clinical trials.
Physical Activity Interventions for Survivors
This sub-topic examines exercise oncology programs improving physical function and reducing recurrence risk in survivors. Researchers study adherence and biomarkers.
Fear of Cancer Recurrence
This sub-topic addresses prevalence, risk factors, and therapeutic management of fear of cancer recurrence among survivors. Researchers develop screening and intervention tools.
Why It Matters
Cancer survivorship and care research provides validated instruments that enable consistent measurement of patient outcomes across international trials, as shown by Aaronson et al. (1993) in 'The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology,' which has supported multicultural clinical research with 15,366 citations. Temel et al. (2010) demonstrated in 'Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer' that early palliative care improved quality of life and mood while reducing aggressive end-of-life care and extending survival by months in 151 patients. Miller et al. (2019, 2022) in 'Cancer treatment and survivorship statistics, 2019' and 'Cancer treatment and survivorship statistics, 2022' quantify the rising survivor population in the United States, aiding public health planning; for instance, these reports highlight needs for services as survivors increase due to early detection and treatment improvements.
Reading Guide
Where to Start
'The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology' by Aaronson et al. (1993), as it provides the foundational, highly cited (15,366 citations) validation of a core quality-of-life tool used across survivorship studies.
Key Papers Explained
Aaronson et al. (1993) 'The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology' establishes a baseline instrument, which Cella et al. (1993) 'The Functional Assessment of Cancer Therapy scale: development and validation of the general measure' complements with the 33-item FACT scale for treatment patients. Temel et al. (2010) 'Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer' applies such measures to show palliative care benefits, while Miller et al. (2019, 2022) 'Cancer treatment and survivorship statistics, 2019' and 'Cancer treatment and survivorship statistics, 2022' contextualize these with population-level data building on Siegel et al. (2012) 'Cancer treatment and survivorship statistics, 2012.' Smets et al. (1995) 'The multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue' and Cella et al. (2010) 'The Patient-Reported Outcomes Measurement Information System (PROMIS)' extend to symptom-specific tools.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent survivorship statistics in Miller et al. (2022) 'Cancer treatment and survivorship statistics, 2022' update survivor numbers amid ongoing population aging and treatment advances, emphasizing public health planning. No preprints or news from the last 12 months indicate steady focus on established instruments like QLQ-C30 and FACT without new disruptions.
Papers at a Glance
Frequently Asked Questions
What is the EORTC QLQ-C30?
The EORTC QLQ-C30 is a quality-of-life instrument developed for use in international clinical trials in oncology. Aaronson et al. (1993) validated it as reliable and valid for measuring quality of life in multicultural cancer patient settings. It has been tested in heterogeneous samples across phase II and III trials.
How does early palliative care affect lung cancer patients?
Early palliative care for metastatic non-small-cell lung cancer patients improves quality of life and mood compared to standard care. Temel et al. (2010) found it led to less aggressive end-of-life care and longer survival. The intervention involved 151 patients in a randomized trial.
What is the FACT scale?
The FACT scale is a 33-item general measure for evaluating quality of life in patients receiving cancer treatment. Cella et al. (1993) developed and validated it through a five-phase process involving 854 patients. It assesses physical, social, emotional, and functional well-being.
What do survivorship statistics show about cancer survivors?
Cancer survivorship statistics indicate an increasing number of survivors in the United States due to population growth, aging, and advances in detection and treatment. Miller et al. (2019, 2022) provide data to assist public health efforts in serving survivors. Earlier reports like Siegel et al. (2012) emphasize the need to understand long-term health and psychosocial effects.
How is fatigue assessed in cancer survivorship?
The Multidimensional Fatigue Inventory (MFI) assesses fatigue through psychometric qualities in cancer patients. Smets et al. (1995) established its reliability for measuring general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue. It serves as a standard tool in survivorship research.
What is the PROMIS system?
The Patient-Reported Outcomes Measurement Information System (PROMIS) developed item banks for adult self-reported health outcomes from 2005–2008. Cella et al. (2010) tested these banks for physical, mental, and social health domains relevant to cancer survivorship. It enables precise measurement of symptoms like fatigue and anxiety.
Open Research Questions
- ? How do changes in EORTC QLQ-C30 scores correlate with patient-perceived significance in diverse cancer types?
- ? What factors drive the increasing prevalence of long-term survivorship needs beyond demographics?
- ? How can PROMIS item banks be optimized for phase II/III trials in heterogeneous survivor populations?
- ? What minimal clinically important differences exist for fatigue measures like MFI in survivorship care?
- ? How do psychosocial interventions impact somatic symptom severity as measured by PHQ-15 in survivors?
Recent Trends
Survivorship statistics reports have progressed from Siegel et al. 'Cancer treatment and survivorship statistics, 2012' (2,945 citations) to Miller et al. (2019) 'Cancer treatment and survivorship statistics, 2019' (4,349 citations) and Miller et al. (2022) 'Cancer treatment and survivorship statistics, 2022' (3,611 citations), consistently attributing survivor increases to population growth, aging, and detection/treatment advances.
2012Citation counts for core instruments remain high, with Aaronson et al. at 15,366 and Cella et al. (1993) at 5,901, reflecting sustained reliance on validated quality-of-life measures.
1993Research Cancer survivorship and care with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cancer survivorship and care with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers